Skip to Main Content

Author Details

Nevena Veljkovic
Heliant Ltd
1999
70
19
PMIDPaper TitleJournal TitlePublished Year
37804398Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study.Drug Saf2023
34850135DisProt in 2022: improved quality and accessibility of protein intrinsic disorder annotation.Nucleic Acids Res2022
33395407Alignment-free method for functional annotation of amino acid substitutions: Application on epigenetic factors involved in hematologic malignancies.PLoS One2021
34298594Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer.Cancers (Basel)2021
34234178The first insight into the genetic structure of the population of modern Serbia.Sci Rep2021
32096820Tally-2.0: upgraded validator of tandem repeat detection in protein sequences.Bioinformatics2020
32078760Deciphering Imidazoline Off-targets by Fishing in the Class A of GPCR field.Mol Inform2020
31713636DisProt: intrinsic protein disorder annotation in 2020.Nucleic Acids Res2020
29446725Mapping of Protein-Protein Interactions: Web-Based Resources for Revealing Interactomes.Curr Med Chem2019
31702762DiNGO: standalone application for Gene Ontology and Human Phenotype Ontology term enrichment analysis.Bioinformatics2019
31719570Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β<sub>2</sub>-adrenergic receptor (β<sub>2</sub>-AR).Sci Rep2019
31744546The CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens.Genome Biol2019
31584358Recent In Silico Resources for Drug Design and Discovery.Curr Med Chem2019
31278492Automated feature engineering improves prediction of protein-protein interactions.Amino Acids2019
30707913Functional characterization of β<sub>2</sub>-adrenergic and insulin receptor heteromers.Neuropharmacology2019
30972303Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.Front Cell Infect Microbiol2019
28930583Ibuprofen as a template molecule for drug design against Ebola virus.Front Biosci (Landmark Ed)2018
30002402IDPpi: Protein-Protein Interaction Analyses of Human Intrinsically Disordered Proteins.Sci Rep2018
30344267Genetic Markers for Coronary Artery Disease.Medicina (Kaunas)2018
27965415Corrigendum: DisProt 7.0: a major update of the database of disordered proteins.Nucleic Acids Res2017
27899601DisProt 7.0: a major update of the database of disordered proteins.Nucleic Acids Res2017
27605104TRI_tool: a web-tool for prediction of protein-protein interactions in human transcriptional regulation.Bioinformatics2017
27265687A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.Bioorg Med Chem2016
32309584Simple Chemoinformatics Criterion Using Electron Donor-Acceptor Molecular Characteristics for Selection of Antibiotics Against Multi-Drug-Resistant Bacteria.Discoveries (Craiova)2016
26598394Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells.Eur J Pharm Sci2016
27604469An expanded evaluation of protein function prediction methods shows an improvement in accuracy.Genome Biol2016
27828989Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China.PLoS One2016
25142184CXCL16 haplotypes in patients with human carotid atherosclerosis: preliminary results.J Atheroscler Thromb2015
26429712Natural Products as Promising Therapeutics for Treatment of Influenza Disease.Curr Pharm Des2015
26733989Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic.Front Microbiol2015
26125997Improving attrition rates in Ebola virus drug discovery.Expert Opin Drug Discov2015
26167272In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.F1000Res2015
25927601Preclinical discovery and development of maraviroc for the treatment of HIV.Expert Opin Drug Discov2015
25717373Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection.F1000Res2015
25745423In silico analysis suggests interaction between Ebola virus and the extracellular matrix.Front Microbiol2015
24783415Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120.Vojnosanit Pregl2014
25401701Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics.PLoS One2014
25045818Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism.Vaccine2014
22429138Simple and general criterion for "in silico" screening of candidate HIV drugs.Curr Pharm Biotechnol2013
24348198Feature-based classification of amino acid substitutions outside conserved functional protein domains.ScientificWorldJournal2013
23658611Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission.PLoS One2013
23167743New in silico and conventional in vitro approaches to advance HIV drug discovery and design.Expert Opin Drug Discov2013
23360165Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study.Comb Chem High Throughput Screen2013
22170451Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.Protein J2012
22467095Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia.J Cell Biochem2012
22261545The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis.J Neuroimmunol2012
21449717A bioinformatics approach to identify natural autoantibodies from healthy blood donors' sera reactive with the HCV NS5A-derived peptide by immunoassay.Viral Immunol2011
22647065The role of long-range intermolecular interactions in discovery of new drugs.Expert Opin Drug Discov2011
22140573Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.PLoS One2011
21684085Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?Med Hypotheses2011
  • 1 - 50 of 70

Recommended Authors

Arthur O Zalevsky
University of California san francisco
Career Start Year 2015
Number of shared co-authors 0
Rehan Zafar Paracha
National University of Sciences and Technology (NUST)
Career Start Year 2012
Number of shared co-authors 0
Jouhyun Jeon
Ontario Institute for Cancer Research
Career Start Year 2008
Number of shared co-authors 1
Raquel Dias
University of Florida
Career Start Year 2008
Number of shared co-authors 4
Jagadish Chandrabose Sundaramurthi
DOE Joint Genome Institute, Lawrence Berkeley National Laboratory
Career Start Year 2008
Number of shared co-authors 2
Nan Zhao
Department of Computer Science and Informatics Institute, University of Missouri
Career Start Year 2007
Number of shared co-authors 1
Khader Shameer
School of Public Health, Imperial College London
Career Start Year 2006
Number of shared co-authors 0
Suwen Zhao
ShanghaiTech University, China iHuman Institute
Career Start Year 2006
Number of shared co-authors 2
Sudipto Saha
Bose Institute
Career Start Year 2005
Number of shared co-authors 1
Jeyakumar Natarajan
Bharathiar University
Career Start Year 2005
Number of shared co-authors 1
Michael Hsing
University of British Columbia
Career Start Year 2004
Number of shared co-authors 0
Dongsup Kim
Korea Advanced Institute of Science and Technology
Career Start Year 2003
Number of shared co-authors 0
Bairong Shen
Institute for Systems Genetics, Western China Hospital, Sichuan University
Career Start Year 2003
Number of shared co-authors 2
Narcis Fernandez-Fuentes
Institute of Biological, Aberystwyth University
Career Start Year 2002
Number of shared co-authors 7
Gerald H Lushington
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Dinesh Gupta
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Career Start Year 2000
Number of shared co-authors 0
Daron M Standley
Osaka university
Career Start Year 1998
Number of shared co-authors 6
Niklas Blomberg
Universitat Tubingen, Institut fur Arbeitsmedizin
Career Start Year 1996
Number of shared co-authors 5
S??ndor Szalma
Takeda California Inc.
Career Start Year 1995
Number of shared co-authors 0
Hualiang Jiang
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Career Start Year 1994
Number of shared co-authors 0
Aw Edith Chan
The Walter and Eliza Hall Institute of Medical Research
Career Start Year 1993
Number of shared co-authors 0
Baldo Oliva
Universitat Pompeu Fabra
Career Start Year 1991
Number of shared co-authors 1
Robert Preissner
Institute for Physiology, Charite-University Medicine Berlin
Career Start Year 1990
Number of shared co-authors 0
Ram Samudrala
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Career Start Year 1990
Number of shared co-authors 0
Herman W T van Vlijmen
Leiden Academic Centre for Drug Research (LACDR), Leiden University
Career Start Year 1988
Number of shared co-authors 0
S??ren Brunak
Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
Career Start Year 1988
Number of shared co-authors 18
Mauno Vihinen
Lund University
Career Start Year 1987
Number of shared co-authors 20
Russ B Altman
Stanford University
Career Start Year 1982
Number of shared co-authors 19
Ruben Abagyan
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 1
Shoba Ranganathan
Macquarie University
Career Start Year 1972
Number of shared co-authors 3

Collaborators

Veljko Veljkovic
Institute of Nuclear Sciences VINCA
Co-authored papers 35
Vladimir Perovic
Institute of Microbiology and Immunology, University of Belgrade
Co-authored papers 35
Sanja Glisic
Vinca Institute of Nuclear Sciences, The University of Belgrade
Co-authored papers 33
Branislava Gemovic
Vinca Institute of Nuclear Sciences, University of Belgrade
Co-authored papers 14
Radoslav Davidovic
Institute of Nuclear Sciences Vinca, University of Belgrade
Co-authored papers 8
Slobodan Paessler
Co-authored papers 7
Neven Sumonja
Institute of Nuclear Sciences VINCA, University of Belgrade
Co-authored papers 6
Silvio C E Tosatto
University of Padova
Co-authored papers 6
Damiano Piovesan
University of Padova
Co-authored papers 6
Federica Quaglia
University of Padova
Co-authored papers 4
Zsuzsanna Dosztányi
Co-authored papers 4
Norman E Davey
The Institute of Cancer Research
Co-authored papers 4
Peter Tompa
VIB-VUB Center for Structural Biology
Co-authored papers 4
Maria Cristina Aspromonte
University of Padova
Co-authored papers 3
Agnes Tantos
Institute of Enzymology, HUN-REN Research Centre for Natural Sciences
Co-authored papers 3
Alan Keith Dunker
Center for Computational Biology, Indiana University School of Medicine
Co-authored papers 3
Daniel B Roche
Universita degli Studi di Milano - Computer Science Department - AnacletoLab
Co-authored papers 3
Beata Szabo
Institute of Enzymology, HUN-REN Research Centre for Natural Sciences
Co-authored papers 3
Marco Necci
Co-authored papers 3
Prajwal Bhat
Royal Holloway University of London
Co-authored papers 2
Matteo Re
Universita degli Studi di Milano
Co-authored papers 2
Vladimir N Uversky
Morsani College of Medicine, University of South Florida
Co-authored papers 2
Burkhard Rost
Technical University of Munich (TUM)
Co-authored papers 2
Alfredo Benso
Italy Consorzio Interuniversitario Nazionale per l'Informatica
Co-authored papers 2
Giuseppe Profiti
University of Bologna
Co-authored papers 2
Kai Hakala
University of Turku
Co-authored papers 2
Christophe Dessimoz
University of Lausanne
Co-authored papers 2
Domenico Cozzetto
Imperial College London
Co-authored papers 2
Maria J Martin
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 2
Marco Mesiti
Universita degli Studi di Milano
Co-authored papers 2
Release 1.2